A leadership experience that turns broad scientific potential into focused therapeutic priorities, clearer decision ownership, and a coordinated path toward the clinic.
Organizational Moment:
Series B financing and transition from platform innovation to therapeutic development
Participants:
12 executive and cross-functional leaders from the U.S. and South Korea
Format:
3 days / 2 nights
Destination + Venue:
West Marin, California · Olema House
Leadership Journey:
Recognition → Reality → Choice → Responsibility → Ownership
Peak Moment:
The First Patient Threshold · Crossing from platform possibility into clinical responsibility
Organizational Value:
Focused therapeutic priorities · Clear decision rights · Stronger cross-border execution
A venture-backed biotechnology company is entering a more consequential stage of growth. After years spent building and validating a differentiated genetic-medicine delivery platform, the organization has secured new financing and begun advancing an internal therapeutic pipeline toward the clinic.
Leadership must now balance continued platform investment with a lead therapeutic program, additional pipeline opportunities, partnerships, and growing capabilities across the U.S. and South Korea.
New funding and a lead program moving toward the clinic are raising the stakes for leadership.
The opportunity is significant, but greater focus is now required. Leaders must decide where to concentrate resources, how to balance platform investment with therapeutic development and partnerships, and how U.S. and South Korean teams will make decisions as one organization.
The offsite creates space to make those choices together and establish the leadership discipline this next stage requires.
The central challenge is narrowing the company's focus without losing the scientific ambition that created its opportunity.
The Experience Arc moves leaders through:
Recognition → Reality → Choice → Responsibility → Ownership
Leaders first recognize the scientific and cross-border contributions that brought the organization to this point. From there, they confront portfolio tradeoffs, clarify decision authority, and establish a more integrated way of operating across the U.S. and South Korea.
As the lead program moves closer to the clinic, those choices take on greater meaning: focus and execution become responsibilities to patients, not simply business priorities.
This team needs enough separation from its Bay Area operating environment to step out of day-to-day demands and make consequential portfolio decisions, without adding unnecessary travel for international participants.
West Marin creates that change of perspective, while Olema House provides the privacy and intimacy required for a 12-person leadership group. Distinct meeting, dining, and outdoor spaces allow the experience to move naturally between rigorous discussion, reflection, recognition, and commitment.
A deliberately unhurried arrival gives U.S. and South Korean participants time to settle in and recover before the work begins. Private transportation, thoughtful rooming, and culturally inclusive hospitality help the group arrive ready to engage.
Leaders then consider two questions:
What must we protect as we scale?
What must now change?
That evening, a private Table of Contribution dinner recognizes specific contributions across functions, disciplines, and geographies, making the interdependence behind the company's progress visible.
After an optional morning walk and relaxed breakfast, the second day centers on decisions. A Portfolio Discipline Lab challenges leaders to make explicit choices among the lead therapeutic program, other internal assets, continued platform investment, and external collaborations.
Those choices are translated into decision rights, escalation paths, milestone governance, and a practical U.S.–South Korea operating rhythm. Focused working sessions are balanced with breaks and outdoor reflection to protect energy before the evening's Peak Moment.
After time to reset, leaders move through two contrasting spaces. The first represents the breadth of scientific possibility the platform has created. The second narrows toward the lead therapeutic program, its critical milestones and dependencies, and the patients the science is intended to serve.
Each leader considers:
What must become more disciplined in my leadership because patients are now closer?
Their commitments become part of a shared installation, while a brief patient or family perspective grounds the moment in the human responsibility behind clinical execution.
A quiet private dinner follows, giving the team space to reflect without adding more formal programming.
The final morning turns the team's choices into an operating system for the next stage: a focused set of organizational priorities, clear decision rights and escalation paths, and a shared cross-border cadence around the lead program.
Each leader identifies one behavior the team should hold them accountable for before the experience closes with a relaxed departure lunch and coordinated return to the Bay Area.
Back at work, the decisions made in West Marin begin shaping how leadership operates day to day. Leadership reviews test whether resources remain concentrated around agreed priorities, decision rules are being used, and cross-border execution is improving.
At 90 days, leaders revisit both their commitments and progress against the operating model established during the offsite.
The lasting value is greater discipline around where the organization invests its time, capital, and leadership attention, with clearer ownership and stronger coordination as the lead program moves toward the clinic.
